HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY 274614

Also Known As:

LY-274614; LY274614; 3-Isoquinolinecarboxylic acid, decahydro-6-(phosphonomethyl)-, (3alpha,4aalpha,6beta,8aalpha)-

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - LY 274614: 4

Related Diseases

1.	Substance Withdrawal Syndrome (Withdrawal Symptoms) 05/02/1991 - "However, competitive NMDA antagonists, like LY274614, could be of great benefit for alleviating opiate withdrawal symptoms in man." 01/01/1991 - "However, competitive NMDA antagonists like LY274614 could be of great benefit for alleviating opiate-withdrawal withdrawal symptoms in man."
2.	Seizures (Absence Seizure) 04/01/1996 - "Systemic (i.p.) treatment with dizocilpine maleate (3 mg/kg) or LY 274614 (5 mg/kg i.p.), two N-methyl-D-aspartate receptor antagonists (given 15 min beforehand), prevented dendrotoxin K (35 pmol)-induced motor seizures and electrocortical epileptogenic discharges in 100% of the animals (n = 6 per group) treated. "
3.	Infections 05/18/1998 - "Administration of the NMDA receptor antagonists MK-801 or LY 274614 ameliorated the decline in striatal met-enkephalin levels observed in mice after 8 weeks of infection. "

Related Drugs and Biologics

1.	Opiate Alkaloids
2.	Dizocilpine Maleate (Dizocilpine)
3.	N-Methylaspartate (NMDA)
4.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
5.	Methionine Enkephalin
6.	dendrotoxin K